Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same
US12319732B2 · kind B2 · utility
0Cited by
2References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 8, 2020 |
| Grant date | Jun 3, 2025 |
| Priority date | — |
| Expiry date | Aug 15, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/7055
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a monoclonal antibody or fragment thereof that recognizes and binds specifically to beta 1 integrin as an antigen. The present invention also relates to a pharmaceutical composition for preventing or treating cancer including the monoclonal antibody or fragment thereof. The monoclonal antibody of the present invention is useful in preventing or treating cancer due to its ability to inhibit the proliferation and angiogenesis of cancer cells and effectively induce apoptosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.